AI주식인사이트AI Stock Insight
B

SK바이오팜

326030KOSPI자연과학 및 공학 연구개발업

60.6 / 100

Reference Date: 2026-06-10

Financial Score23.5 / 40
News Sentiment17.1 / 25
Momentum8.0 / 20
Disclosure12.0 / 15
AI Analysis: PER is significantly undervalued vs. peers but PBR raises overvaluation concerns. Declined 7.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

SK Bios制药 was established in 1993, focusing on innovative drug development for epilepsy and successfully expanding its technology exports to multiple countries, including the U.S. and Europe. Its flagship products, Xenobamate and Solriamfetol, are sold in global markets, with sales reaching 70.67 billion KRW in 2025. The company is also advancing into new therapeutic modalities such as RPT and TPD to expand into oncology.

Number of Employees

272people

Average Salary

109.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
26.96Industry Average 62.708.0Point

Half of industry avg (excellent)

PBR
8.71Industry Average 3.240.0Point

2.7x industry avg (risky)

ROE
36.17Industry Average -32.093.5Point

Well below industry avg

Debt Ratio
9.30Industry Average 7.312.0Point

Higher than industry avg (caution)

Trend 2023~202510.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲41.7% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲234.2% (2-year basis)

ROE Trend
4.0 / 4

Avg ROE 25.3% (improving, 3yr)

Detailed News Sentiment

24 totalPositive 12Neutral 9Negative 3Average Sentiment Score 68.5

Detailed Momentum

52-week position1.0Point

Near 52w low (7%, downtrend)

Current 91,900Won52-week high 140,70052-week low 88,100
1-month return1.0Point

1m -7.73% (falling)

Volume trend6.0Point

Volume surge

Detailed Disclosure

6 totalPositive 1Neutral 5Negative 0
  • Neutral기업지배구조보고서공시2026-06-01
  • Neutral대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]2026-05-29
  • Positive단일판매ㆍ공급계약체결2026-05-27
  • Neutral기업설명회(IR)개최(안내공시)2026-05-26
  • Neutral기업설명회(IR)개최(안내공시)2026-05-19